GSK(GSK) - 2025 Q1 - Quarterly Report

Transaction in Own Shares This section outlines GSK plc's share buyback activities, including purchase specifics, program context, and transaction schedules Summary of Share Purchase On April 29, 2025, GSK plc purchased 685,000 of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited, to be held as Treasury shares Share Purchase Details (April 29, 2025) | Metric | Value | | :--- | :--- | | Date of purchase | 29 April 2025 | | Aggregate number of ordinary shares purchased | 685,000 | | Lowest price paid per share (GBp) | 1,404.50p | | Highest price paid per share (GBp) | 1,435.00p | | Volume-weighted average price paid per share (GBp) | 1,421.25p | Buyback Programme Context This share purchase is part of GSK's existing buyback programme, initiated under a non-discretionary agreement with its broker on February 24, 2025, resulting in over 204 million shares held in treasury - The purchase is part of an existing buyback programme under an agreement with Citigroup Global Markets Limited, announced on February 24, 2025[5] Share Capital Status After Purchase | Metric | Number of Shares | | :--- | :--- | | Total shares purchased since 24 Feb 2025 | 35,034,155 | | Ordinary shares held in treasury | 204,104,458 | | Ordinary shares in issue (excluding Treasury) | 4,111,136,920 | Shareholder Information The total number of voting rights in the company is 4,111,136,920, serving as the denominator for shareholders to calculate notification requirements under FCA rules - The total number of voting rights in the Company is 4,111,136,920, which shareholders can use to determine if they are required to notify their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules[6] Schedule of Purchases The report provides a detailed schedule of all share purchases made on April 29, 2025, including aggregated information by trading venue and a comprehensive list of individual transactions Aggregated Information per Trading Venue All 685,000 shares were purchased on the London Stock Exchange (XLON) at a volume-weighted average price of 1,421.25p, with no trades executed on CBOE (BATE or CHIX) Aggregated Purchases on London Stock Exchange (XLON) | Venue | Number of Shares | Highest Price (GBp) | Lowest Price (GBp) | VWAP (GBp) | | :--- | :--- | :--- | :--- | :--- | | London Exchange (XLON) | 685,000 | 1,435.00p | 1,404.50p | 1,421.25p | Individual Transactions A comprehensive list details every individual trade executed as part of the buyback on April 29, 2025, including trade time, volume, price, trading venue, and a unique transaction ID - The report includes a detailed breakdown of all individual transactions made by the broker on the London Stock Exchange[7][9] Cautionary Statement GSK includes a cautionary statement warning investors that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected, referring investors to its 2024 Annual Report on Form 20-F for more details - GSK cautions that forward-looking statements are subject to risks and uncertainties which may cause actual results to differ from projections[46] - Investors are directed to the Risk Factors section on pages 277 to 285 of the GSK 2024 Annual Report on Form 20-F for further details[46] Signatures The report was duly signed and authorized on behalf of GSK plc on April 30, 2025, by Victoria Whyte, in accordance with the requirements of the Securities Exchange Act of 1934 - The report is signed by Victoria Whyte, an authorized signatory for GSK plc, on April 30, 2025[94]